Floatz logo

Liraglutide

Pulmonary Disease, Chronic Obstructive

Claus Bogh Juhlprotein_peptidePhase 4 / ApprovedDormant
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
95/ 100

Competitive context

22 Active assets in the Pulmonary Disease, Chronic Obstructive cohort.

Asset / SponsorPhaseRating
Roflumilast
Prince of Songkla University
Phase 3BB
Ciprofloxacin
Chronic Obstructive Pulmonary Disease Trial Network, Denmark
Phase 4BB
Piperacillin
Chronic Obstructive Pulmonary Disease Trial Network, Denmark
Phase 4BB
.ALPHA.-1 PROTEASE INHIBITOR
Takeda
Phase 4BB
20-valent pneumococcal conjugate vaccine
University of Alabama at Birmingham
Phase 4BB

View all 50 →

Same molecule, other indications

Liraglutide is also rated in:

metabolic diseaseDormant
A
Indicative ·
84 / 100
View asset →
polycystic ovary syndromeDormant
BBB
Indicative ·
79 / 100
View asset →
type 2 diabetes mellitusDormant
BBB
Indicative ·
79 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →